Psma1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@nguyen2021]
Overview
PSMA1 (Proteasome Subunit Alpha Type 1) encodes the α1 subunit of the 20S proteasome core particle, a crucial component of the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS) responsible for targeted protein degradation in all eukaryotic cells. In the brain, PSMA1 is expressed in [neurons](/entities/neurons) and glia where it plays essential roles in maintaining [protein homeostasis](/mechanisms/protein-quality-control-network)), clearing misfolded proteins, and regulating synaptic function. Dysfunction of PSMA1 and the proteasome complex is strongly implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), and [Huntington's disease](/diseases/huntington-disease). [@kikuchi2020]
Psma1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@nguyen2021]
Overview
PSMA1 (Proteasome Subunit Alpha Type 1) encodes the α1 subunit of the 20S proteasome core particle, a crucial component of the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) (UPS) responsible for targeted protein degradation in all eukaryotic cells. In the brain, PSMA1 is expressed in [neurons](/entities/neurons) and glia where it plays essential roles in maintaining [protein homeostasis](/mechanisms/protein-quality-control-network)), clearing misfolded proteins, and regulating synaptic function. Dysfunction of PSMA1 and the proteasome complex is strongly implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), and [Huntington's disease](/diseases/huntington-disease). [@kikuchi2020]
| Property | Value | [@deng2021] |----------|-------| [@sitte2020] | Protein Name | Proteasome Subunit Alpha Type 1 | | Gene | [PSMA1](/genes/psma1) | | UniProt ID | [P25786](https://www.uniprot.org/uniprot/P25786) | | PDB ID | [5MX3](https://www.ebi.ac.uk/pdbe/5MX3) | | Molecular Weight | 27.6 kDa | | Subcellular Localization | Cytoplasm, Nucleus | | Protein Family | Proteasome alpha subunit family | | Expression | Ubiquitous, high in brain |
</div>
Structure
The PSMA1 protein is a 263-amino acid subunit that adopts the classic α/β fold shared by all proteasome subunits. Each subunit contains an N-terminal threonine residue (Thr1) that serves as the catalytic nucleophile for proteolysis.
Quaternary Structure
The 20S proteasome forms a barrel-shaped complex composed of four stacked heptameric rings:
Outer α-rings: Composed of PSMA1-7, forming the substrate entry gate
Inner β-rings: Composed of PSMB1-7, containing the proteolytic sites (PSMB5, PSMB6, PSMB7)
The α-rings regulate substrate access through the gated channel mechanism, controlled by regulatory particles (19S/PA700) or proteasome activators (PA28/11S, Blm10/PA200).
Post-Translational Modifications
PSMA1 undergoes various modifications including:
Phosphorylation (affects proteasome assembly and activity)
Acetylation (alters substrate recognition)
Oxidative modifications (can impair function in aging brains)
Normal Function
PSMA1 is essential for proteasome assembly and catalytic function:
Protein Degradation
Proteolysis: The α-ring contributes to the structural integrity of the proteolytic chamber
Substrate recognition: PSMA1 contains binding sites for ubiquitin tags
Gate regulation: Controls entry of substrates into the proteolytic core in response to regulatory particles
Cellular Homeostasis
Protein quality control: Degrades damaged, oxidized, and misfolded proteins
Cell cycle regulation: Processes cyclins and cell cycle regulators
Stress response: Clears stress-induced protein aggregates
Neuronal Specific Functions
Synaptic protein turnover: Regulates synaptic plasticity through degradation of synaptic proteins
Neurotransmitter receptor regulation: Controls AMPA and [NMDA receptor](/entities/nmda-receptor) subunit composition
Axonal transport: Facilitates degradation of transport complex components
Role in Neurodegenerative Diseases
Alzheimer's Disease
Proteasome dysfunction is a hallmark of AD brains:
Impaired [20S proteasome activity](/mechanisms/ubiquitin-proteasome-system) contributes to [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) accumulation
PSMA1 levels are reduced in AD temporal [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
Oxidative stress damages PSMA1, creating a vicious cycle of proteasome impairment and protein aggregation
[Tau](/proteins/tau) oligomers can directly inhibit proteasome function
The study of Psma1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[PubMed: PSMA1 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PSMA1+neurodegeneration) — Literature search
References
[Groll M, et al., Structure of 20S proteasome from yeast at 2.4Å resolution. Nature. 1997;386(6624):463-471 (1997)](https://doi.org/10.1038/386463a0)
[Unknown, Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med. 2015;47:e147 (2015)](https://doi.org/10.1038/emm.2014.117)
[Unknown, Thibaudeau TA, Anderson RT, Smith JR. Proteasome as a therapeutic target in neurodegenerative disease. Curr Pharm Des. 2013;19(18):3260-3274 (2013)](https://pubmed.ncbi.nlm.nih.gov/23431944/)
[Unknown, Nguyen P, Barakat A, Mook-Jung I. Proteasome modulation as a therapeutic approach in Alzheimer's disease. Front Aging Neurosci. 2021;13:630853 (2021)](https://doi.org/10.3389/fnagi.2021.630853)
[Kikuchi M, et al., Proteasome impairment in neural cells by amyloid-beta peptide. J Neurochem. 2020;152(3):381-395 (2020)](https://doi.org/10.1111/jnc.14905)
[Zhang J, et al., alpha-Synuclein and proteasome in Parkinson's disease: a dangerous liaison. J Neural Transm (Vienna). 2018;125(3):461-472 (2018)](https://doi.org/10.1007/s00702-017-1730-9)
[Deng H, et al., TDP-43 pathology in ALS: proteasome impairment and stress granule formation. Acta Neuropathol. 2021;141(2):173-186 (2021)](https://doi.org/10.1007/s00401-020-02217-0)
[Sitte S, et al., Proteasome inhibition leads to early synaptic dysfunction in Huntington's disease. J Neurosci. 2020;40(12):2412-2424 (2020)](https://doi.org/10.1523/JNEUROSCI.2049-19.2020)